NOREPINEPHRINE BITARTRATE Drug Patent Profile
✉ Email this page to a colleague
When do Norepinephrine Bitartrate patents expire, and when can generic versions of Norepinephrine Bitartrate launch?
Norepinephrine Bitartrate is a drug marketed by Amneal, Baxter Hlthcare Corp, Breckenridge, Caplin, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Meitheal, Metrics Pharm, Mylan Labs Ltd, Sandoz, Sun Pharm, Zydus Pharms, Inforlife, and Long Grove Pharms. and is included in seventeen NDAs. There are seven patents protecting this drug.
The generic ingredient in NOREPINEPHRINE BITARTRATE is norepinephrine bitartrate. There are five drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate
A generic version of NOREPINEPHRINE BITARTRATE was approved as norepinephrine bitartrate by MEITHEAL on March 3rd, 2003.
Summary for NOREPINEPHRINE BITARTRATE
US Patents: | 0 |
Applicants: | 15 |
NDAs: | 17 |
Finished Product Suppliers / Packagers: | 16 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 8 |
Patent Applications: | 4 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for NOREPINEPHRINE BITARTRATE |
What excipients (inactive ingredients) are in NOREPINEPHRINE BITARTRATE? | NOREPINEPHRINE BITARTRATE excipients list |
DailyMed Link: | NOREPINEPHRINE BITARTRATE at DailyMed |
Recent Clinical Trials for NOREPINEPHRINE BITARTRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tunis University | Phase 4 |
Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
Wright State University | Phase 3 |
Pharmacology for NOREPINEPHRINE BITARTRATE
Drug Class | Catecholamine |
Medical Subject Heading (MeSH) Categories for NOREPINEPHRINE BITARTRATE
Anatomical Therapeutic Chemical (ATC) Classes for NOREPINEPHRINE BITARTRATE
US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Grove Pharms | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214628-003 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Long Grove Pharms | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214628-002 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Long Grove Pharms | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214628-003 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Long Grove Pharms | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214628-002 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |